
Veru (VERU) Stock Forecast & Price Target
Veru (VERU) Analyst Ratings
Bulls say
Veru Inc. is actively engaged in the development of innovative therapies targeting cardiometabolic and inflammatory conditions, with its leading candidates, enobosarm and sabizabulin, poised to enter critical Phase 2 clinical studies. The substantial revenue growth seen in the broader obesity treatment market—such as Zepbound's reported $3.6 billion in Q3 2025, reflecting a 185% year-over-year increase—demonstrates an escalating demand and a lucrative opportunity for Veru's offerings. Furthermore, the anticipated expansion of GLP-1RA therapies into new indications and the absence of approved muscle-preserving medications indicate a compelling market potential for Veru’s unique treatment strategies.
Bears say
Veru Inc faces significant risks related to the potential failure of its late-stage development programs for enobosarm and sabizabulin, which could impede future revenue growth and negatively impact stock performance. Additionally, the company is encountering intense competition in its development programs, raising concerns about the possibility of lower than anticipated revenues and increased regulatory scrutiny from the FDA regarding efficacy and safety requirements. Furthermore, high turnover in key regulatory agency-facing roles, such as the CEO and CMO, may further destabilize the company, contributing to an unfavorable outlook for its stock performance.
This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.
Veru (VERU) Analyst Forecast & Price Prediction
Start investing in Veru (VERU)
Order type
Buy in
Order amount
Est. shares
0 shares